Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Trial details
- Registry ID
- NCT06943755
- Phase
- Phase 2, Phase 3
The FDA approved Everolimus (Afinitor) on 30 Mar 2009.
Drug identity checked against registry records
Also recorded as Afinitor
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755 | Exelixis | Phase 2, Phase 3 | Recruiting | 2029-06-30Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2009-03-30Day | Everolimus | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA022334", "applicant_as_listed_by_fda": "NOVARTIS", "brand_names": ["AFINITOR"], "active_ingredients": ["EVEROLIMUS"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20090330", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |